{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:00:17Z","timestamp":1791309617646,"version":"4.3.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"European and Developing Countries Clinical Trials Partnership (EDCTP) 2","award":["CSA2016S-1618"],"award-info":[{"award-number":["CSA2016S-1618"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40264-024-01469-7","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T08:02:25Z","timestamp":1724140945000},"page":"1193-1202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Short-Term Training, a Useful Approach for Sustainable Pharmacovigilance Knowledge Development in Tanzania, Kenya, Ethiopia and Rwanda"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2236-1398","authenticated-orcid":false,"given":"Eug\u00e8ne","family":"van Puijenbroek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbie","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-9920","authenticated-orcid":false,"given":"Christabel","family":"Khaemba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazare","family":"Ntirenganya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-9916","authenticated-orcid":false,"given":"Tigist Dires","family":"Gebreyesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9356-2218","authenticated-orcid":false,"given":"Adam","family":"Fimbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8692-1924","authenticated-orcid":false,"given":"Omary","family":"Minzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-5288","authenticated-orcid":false,"given":"Eyasu","family":"Makonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4881-8667","authenticated-orcid":false,"given":"Margaret","family":"Oluka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Guantai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-0790","authenticated-orcid":false,"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"issue":"2","key":"1469_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bcp.15193","volume":"89","author":"R Kiguba","year":"2023","unstructured":"Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2023;89(2):491\u2013509.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1469_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1586\/17512433.2015.1053391","volume":"8","author":"S Olsson","year":"2015","unstructured":"Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8(4):449\u201360.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1469_CR3","unstructured":"Roadmap for access to medicines, vaccines and health product 2019-2023: comprehensive support for access to medicines, vaccines and other health products. World Health Organization; 2019."},{"key":"1469_CR4","unstructured":"Website PROFORMA. Pharmacovigilance infrastructure and post-marketing surveillance system capacity building for regional medicine regulatory harmonization in East Africa. Available from https:\/\/proforma.ki.se\/#."},{"issue":"4","key":"1469_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40264-019-00898-z","volume":"43","author":"A Barry","year":"2020","unstructured":"Barry A, Olsson S, Minzi O, Bienvenu E, Makonnen E, Kamuhabwa A, et al. Comparative assessment of the national pharmacovigilance systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. Drug Saf. 2020;43(4):339\u201350.","journal-title":"Drug Saf"},{"key":"1469_CR6","unstructured":"ICH guideline Q9 on quality risk management. European Medicines Agency."},{"key":"1469_CR7","unstructured":"Guidelines for Qualified Person for Pharmacovigilance [press release]. Ghana Food and Drugs Authority; 2013."},{"issue":"3","key":"1469_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jsps.2016.09.008","volume":"25","author":"TM Alshammari","year":"2017","unstructured":"Alshammari TM, Alshakka M, Aljadhey H. Pharmacovigilance system in Saudi Arabia. Saudi Pharm J. 2017;25(3):299\u2013305.","journal-title":"Saudi Pharm J."},{"issue":"1","key":"1469_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12992-018-0431-0","volume":"14","author":"HH Ampadu","year":"2018","unstructured":"Ampadu HH, Hoekman J, Arhinful D, Amoama-Dapaah M, Leufkens HGM, Dodoo ANO. Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences. Glob Health. 2018;14(1):109.","journal-title":"Glob Health"},{"issue":"3","key":"1469_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3163\/1536-5050.103.3.010","volume":"103","author":"NE Adams","year":"2015","unstructured":"Adams NE. Bloom\u2019s taxonomy of cognitive learning objectives. J Med Libr Assoc. 2015;103(3):152\u20133.","journal-title":"J Med Libr Assoc"},{"issue":"5","key":"1469_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO global ICSR database system. Drug Inf J. 2008;42(5):10.","journal-title":"Drug Inf J"},{"key":"1469_CR12","unstructured":"The National Pharmcovigilance Roadmap 2019\u20132023. Tanzania Medicines and Medical Devices Authority; 2021."},{"key":"1469_CR13","unstructured":"Adverse event reporting in the palm of your hand: Uppsala Monitoring Centre; 2024. Available from https:\/\/who-umc.org\/pv-products\/vigiflow\/vigimobile\/."},{"issue":"1","key":"1469_CR14","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1186\/s12889-022-13867-6","volume":"22","author":"JU Stegmann","year":"2022","unstructured":"Stegmann JU, Jusot V, Menang O, Gardiner G, Vesce S, Volpe S, et al. Challenges and lessons learned from four years of planning and implementing pharmacovigilance enhancement in sub-Saharan Africa. BMC Public Health. 2022;22(1):1568.","journal-title":"BMC Public Health"},{"issue":"6","key":"1469_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40264-020-00925-4","volume":"43","author":"V Jusot","year":"2020","unstructured":"Jusot V, Chimimba F, Dzabala N, Menang O, Cole J, Gardiner G, et al. Enhancing pharmacovigilance in sub-Saharan Africa through training and mentoring: a GSK pilot initiative in Malawi. Drug Saf. 2020;43(6):583\u201393.","journal-title":"Drug Saf"},{"issue":"4","key":"1469_CR16","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/bcp.14179","volume":"86","author":"CR Herrera","year":"2020","unstructured":"Herrera CR. Undergraduate and postgraduate pharmacovigilance education: a proposal for appropriate curriculum content. Br J Clin Pharmacol. 2020;86(4):779\u201390.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1469_CR17","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.3390\/ijerph18041941","volume":"18","author":"A Barry","year":"2021","unstructured":"Barry A, Olsson S, Khaemba C, Kabatende J, Dires T, Fimbo A, et al. Comparative assessment of the pharmacovigilance systems within the neglected tropical diseases programs in East Africa-Ethiopia, Kenya, Rwanda, and Tanzania. Int J Environ Res Public Health. 2021;18(4):1941.","journal-title":"Int J Environ Res Public Health."},{"issue":"11","key":"1469_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s40264-018-0681-z","volume":"41","author":"R van Eekeren","year":"2018","unstructured":"van Eekeren R, Rolfes L, Koster AS, Magro L, Parthasarathi G, Al Ramimmy H, et al. What future healthcare professionals need to know about pharmacovigilance: introduction of the WHO PV core curriculum for university teaching with focus on clinical aspects. Drug Saf. 2018;41(11):1003\u201311.","journal-title":"Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01469-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01469-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01469-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T14:09:52Z","timestamp":1731334192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01469-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1469"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01469-7","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"16 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This short-term training was part of the \u201cPharmacovigilance infrastructure and post-marketing surveillance system capacity building for regional medicine regulatory harmonization in East Africa\u201d (PROFORMA) project supported by the European and Developing Countries Clinical Trials Partnership (EDCTP) 2 programme supported by the European Union (grant number CSA2016S-1618).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Eug\u00e8ne van Puijenbroek is an Editorial Board member of <i>Drug Safety<\/i>. Eug\u00e8ne van Puijenbroek was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. All other authors declare no relevant conflicts of interest relevant to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The code of the e-learning modules developed is not available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not Applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The design of the manuscript was determined by EvP. The baseline assessment was conducted by AB. Views from academic institutions and national medicines regulatory authorities were provided by AB, CK, LN, TDG, AF, OM, EM, MO, AG and EL. All authors contributed to manuscript drafting and revision. All authors approved the final version to be published and agreed to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}